

 **Mission of AABC**

The mission of the Alzheimer's Association® Business Consortium (AABC) is to advance Alzheimer's disease research and innovation in small- and medium-size biotechnology, diagnostics, medical device and contract research organizations.

AABC members work in areas of common interest pre-competitively to advance both the field of Alzheimer's research and the goals of its member organizations. They provide leadership and direction to the groups' areas of focus, which include, but are not limited to, collaborations, recognition and visibility, and knowledge and information sharing. AABC welcomes new member organizations who are aligned in their commitment to research and innovation. To express interest in joining, please email co-chairs Dr. Theresa Devins (tdevins@cogr.com) or Dr. Paul Slowey (pds@4saliva.com), or Dr. Christopher Weber (cweber@alz.org), facilitator.

 **Welcome New Members**

AABC is growing! Welcome to:

» Anuj Guruacharya, PhD & Bini Raj, PhD, Nanil Therapeutics

Nanil Therapeutics develops AI-designed, brain-penetrant biologics and aptamers for Alzheimer's and related dementias. Our platform uses generative modeling, multi-objective optimization, and active learning to propose candidates with improved developability, target engagement, and CNS delivery potential. We integrate human iPSC-based assays to create a closed-loop design—make—test—learn cycle that advances the most promising programs quickly and transparently. As part of the Alzheimer's Association Business Consortium, we aim to contribute tools, data, and an AI-augmented approach that moves disease-modifying therapies closer to patients.

» Stanley Durrleman, & Kuno van der Post, MSc., PhD, Qairnel

Qairnel develops DocMemo.com, an AI-powered platform designed to detect early cognitive complaints in the general population. By collecting and analyzing a wide range of digital data and biomarkers, DocMemo helps qualify cognitive concerns, reassure the "worried well," and guide individuals at risk toward appropriate healthcare professionals or clinical trials. Our volunteer qualification technology significantly reduces screen failure rates at recruiting sites, cutting both recruitment costs and timelines by up to fourfold. [Qairnel also leverages a proprietary digital twin technology that has demonstrated best-in-class predictive accuracy for cognitive decline.](#) In both simulations and real-world use cases, this technology has been shown to reduce the number of participants required for clinical trials by up to 50%. With more than 30,000 individuals screened in just a few months through the DocMemo platform, and with advanced AI tools that better characterize trial participants, Qairnel is positioning itself as a key enabler of more powered and efficient clinical trials in Alzheimer's disease and related disorders.

» Katie Flores, Kim Johnson, David Lucas, & Eric Rock

Percipio Health supports earlier detection and more proactive care by making whole-person health data easier to capture and act on, especially for conditions that often go undiagnosed such as cognitive decline. Using only a patient's smartphone, the platform collects vital, behavioral, and cognitive health signals without the need for additional devices. Advanced analytics and AI then translate this data into timely risk insights and care guidance for clinical teams. The result is earlier identification of change, faster interventions, reduced burden on care teams, and improved support for individuals at risk of dementia and related conditions. Learn more at percipiohealth.com.



712 North Inc. obtains a new patent.

712 North Inc., a California-based pre-clinical pharmaceutical company, announced on November 11, 2025, that a new patent entitled "Tricyclic compounds with OMA1/OPA1 modulatory properties" was granted by the United States Patent and Trademark Office (USPTO).

712 North develops personalized mitochondrial medicines for patients with Alzheimer's and other age-related diseases. Mitochondrial impairments are well recognized in these conditions. Mitochondria are dynamic organelles whose morphology is intimately linked to energy metabolism, quality-control pathways, and stress responses. The OMA1 protease is a master regulator at the center of these processes, ultimately deciding cell fate. The new patent covers tricyclic compounds, including novel dibenzoxazepin derivatives, that were found to modulate OMA1. These compounds are potentially useful for treating various age-related conditions and diseases. 712 North's core technology centers around a proprietary cellular OMA1 protease assay used to discover these molecules. For more information, please visit www.712north.com.

ADvantage Therapeutics Awarded \$2.5 million NIH SBIR Grant to Advance Alzheimer's Drug Candidate AD04® Toward the Clinic

ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, today announced it has been awarded a \$2.5 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging of the National Institutes of Health (NIH). This non-dilutive grant will further important research supporting AD04®, the company's phase 2 Alzheimer's candidate.

This news follows the recent publication of encouraging AD04® results in The Journal of Prevention of Alzheimer's Disease (JPAD) <https://pubmed.ncbi.nlm.nih.gov/40953123/>. The publication highlighted encouraging results from AD04's earlier Phase 2 trial. A follow-up independent statistical analysis confirmed that the positive effects seen in patients were reliable and not due to chance. These findings suggest that AD04 produced a treatment effect that compared favorably to monoclonal Alzheimer's therapies already on the market, while being easier to take, safer, and more affordable. See more at the Press [Release here](#).

Oasis Diagnostics® and UCM Announce Partnership Enabling At-Home Saliva Collection for Next-Gen. Cancer Screening Test

Oasis Diagnostics® Corporation and UCM Technologies Announce Partnership to Enable At-Home Saliva Collection for Next-Generation Cancer Screening Test

UCM Technologies Inc., developer of the next-generation cancer screening test based on the CA-62 biomarker, today announced the signing of a Memorandum of Understanding (MOU) with Oasis Diagnostics® Corporation (Vancouver, WA, USA). The partnership aims to integrate UCM's proprietary early cancer detection assay with Oasis's advanced saliva collection technology, paving the way for convenient, non-invasive, at-home testing. More information can be found on the [Press Release](#).

Upcoming Conferences

AAIC 2026 Abstract Submission

Abstract submissions for the [Alzheimer's Association International Conference® \(AAIC®\) 2026](#) are now open. Join us in London, July 12-15, 2026, to share your latest findings, exchange ideas and inspire progress alongside the global leaders advancing Alzheimer's and dementia science and clinical practice.

Alzheimer's Association Neuroscience Next | Feb 23-26, 2026

AAIC Neuroscience Next is a global, no-cost hybrid conference that aims to support and showcase the next generation of Alzheimer's and dementia researchers and clinicians. The program is presented in a hub format that connects both global and local communities. [Register here.](#)

Seventh International Neuro4D Conference, May 4-5, 2026, Mainz, Germany

[Neuro4D 2026](#) focusses on novel treatments for proteopathic neurodegenerative diseases, like Alzheimer's disease, Parkinson's disease, ALS, FTD, etc.. The draft program will be online in early 2026 and early bird registration with savings of up to 400 € is available until March 1, 2026!

Exhibitors and sponsors, please request the 'Costs & Packages' document. Speakers are welcome to apply by sending a suggested title and abstract of their intended presentation. 2026 we will focus again on novel mechanisms for treating neurodegeneration. We will also hear more about disease-induced neuroinflammation and how it might be stopped. As always, the second day program focuses on clinical insights, biomarkers and market success of recent successful product launches.

Neuro4D brings a maximum of 100 distinguished industry and academic speakers, poster presenters and delegates in neurodegenerative disease in direct contact, and creates lively discussions about drug discovery efforts for two full days, in a stimulating and enjoyable setting. Feedback forms always show highest marks from all participants! Academic experts outline recent insights into the complex disease mechanisms. Biotech and pharmaceutical drug companies present their developments for new treatment options. Service providers present their platforms and show examples of how their services contribute to new drug candidate discovery. By the end of the conference, all participants got to know each other, which already resulted in many new productive collaborations.

The Neuro4D Conference is the most interactive conference that you will have ever attended!

Social Media

Follow our [LinkedIn](#) page! We look forward to using the page to foster partnerships and communications.

Spread the Word

To help us grow AABC, please continue to introduce new members and companies to our group. We also welcome ideas or events for this newsletter so we can better serve you. Please send your suggestions to Ashley Hansen at (ahansen@alz.org).